In mouse and rat tests, the peptide semax and some new 3‑hydroxypyridine compounds helped animals survive longer when they were suddenly deprived of oxygen, especially under stressful conditions like pancreatitis. The best‑performing compounds (SK‑100 and IBKhF‑2) boosted life span by about 25‑40% at doses of 10‑100 mg per kilogram of body weight, similar to other known anti‑hypoxia drugs.

Experiments with occlusion of the common carotid artery in mice demonstrated that, unlike mexidol and SK-170, single injection of new derivatives of 3-hydroxypyridine (3-HP) SK-100 and IBKhF-2, and semax have an anti-hypoxic action on the model of acute normobaric hypoxia with hypercapnia. In analogous experiments with rats the distinct anti-hypoxic action was produced by 4 new 3-HP derivatives (SK-100, SK-170, IBKhF-22 at the dose of 100 mg/kg and IBKhF-2 at the doses of 10 and 30 mg/kg--extension of life span by 25-39%), mexidol (100 mg/kg) and reference-class antihypoxant amtisol (30 mg/kg, life span expansion by 19 and 27%, respectively). A series of experiments with rats with acute pancreatitis, a distinct anti-hypoxic action was shown by SK-100, SK-170 at 100 mg/kg and IBKhF at 10 and 30 mg/kg (life span extension by 26-40%), mexidol (100 mg/kg) and amtisol (30 mg/kg) which extended life span by 17 and 22%, respectively. Therefore, SK-100 and IBKhF-2 are potent to prolong life span of equally mice and rats; SK-170 and mexidol were effective only in experiments with rats.